Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Novo Nordisk, Gilead team up to test NASH treatment

Written by: | no-reply@reuters.com | Dated: Friday, April 12th, 2019

 

Novo Nordisk and Gilead team up to test fatty liver disease treatment

 

COPENHAGEN (Reuters) – Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

The clinical trial will be a study combining Novo Nordisk’s semaglutide drug and Gilead’s cilofexor and firsocostat for treatment of patients with Nonalcoholic steatohepatitis (NASH), Novo Nordisk, best known for its diabetes drugs, said on Friday.

“NASH is a complex disease that often affects people with diabetes and metabolic syndrome. Currently, patients living with NASH have limited treatment options,” said Gilead’s chief scientific officer John McHutchison in a statement.

In February, Gilead said a late-stage study of the experimental drug selonsertib aimed at treating NASH failed to meet its main goal.

Analysts have projected the market for NASH treatments to reach $20 billion to $35 billion as populations increasingly develop the disease fueled by obesity and diabetes.

Without treatment, sufferers can develop advanced damage, including the scarring known as fibrosis; cirrhosis, which destroys liver function; and even cancer.

Novo is currently testing semaglutide, already approved to treat diabetes, as a once-daily treatment for NASH in phase 2. Gilead’s Cilofexor and firsocostat have not been approved by any regulatory authorities.

 

Reporting by Stine Jacobsen; Editing by Keith Weir

 

Reuters source:

https://www.reuters.com/article/us-novo-nordisk-gilead-sciences-nash/novo-nordisk-and-gilead-team-up-to-test-fatty-liver-disease-treatment-idUSKCN1RO0Y3

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom